摘要
目的:探讨氟维司群联合阿那曲唑治疗雌激素受体(Estrogen receptor,ER)阳性的晚期乳腺癌(Advanced breast cancer,ABC)患者的临床疗效。方法:选取2012年1月至2022年1月三门峡市中心医院收治的232例ER阳性ABC患者作为研究对象进行回顾性分析,根据治疗方案不同,分为阿那曲唑组和氟维司群联合组,各116例。比较两组患者的疗效、中位无进展生存期(Progression free survival,PFS)、总生存期(Overall survival,OS)、不良反应发生率。结果:氟维司群联合组的临床获益率(Clinical benefit rate,CBR)、PFS和OS明显高于阿那曲唑组(P<0.05);两组客观缓解率(Objective response rate,ORR)和不良反应发生率无明显差异(P>0.05)。结论:氟维司群联合阿那曲唑治疗ER阳性ABC患者,可显著提升CBR,延长PFS和OS,但未显著增加不良反应,具有较高的用药安全性。
Objective:To investigate the clinical efficacy of fluvastatin combined with anastrozole in the treatment of estrogen receptor(ER)positive patients with advanced breast cancer(ABC).Methods:A total of 232 ABC patients with ER positive who were admitted to Sanmenxia Central Hospital from January 2012 to January 2022 were selected.According to different treatment plans,they were divided into anastrozole group and fluvastatin combination group,with 116 patients in each group.The curative effect,median progression free survival(PFS),overall survival(OS)and adverse reaction rate were compared between the two anastrozole group and fluvastatin combination group.Results:The clinical benefit rate(CBR),PFS and OS of the fluvastatin combination group were significantly higher than those of the anastrozole group(P<0.05).There was no significant difference in the objective response rate(ORR)and the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Fluvastatin combined with anastrozole in the treatment of ER positive ABC patients can significantly improve CBR,prolong PFS and OS,but it does not significantly increase adverse reactions,with a higher safety.
作者
朱云朋
刘艳
陈威鹏
Zhu Yun-peng;Liu Yan;Chen Wei-peng(Department of Nail and Breast Surgery,Sanmenxia Central Hospital,Sanmenxia 472000,Henan,China;Department of Gynecology,Sanmenxia Central Hospital,Sanmenxia 472000,Henan,China)
出处
《四川生理科学杂志》
2023年第12期2237-2240,共4页
Sichuan Journal of Physiological Sciences
基金
三门峡市2021年科技发展计划项目(2021004032)
。
关键词
氟维司群
阿那曲唑
晚期乳腺癌
雌激素受体阳性
临床疗效
Fluvastatin
Anatrozole
Advanced breast cancer
Estrogen receptor positive
Clinical efficacy
